6671-85-8

Basic information

• Product Name: 2-Azabicyclo[2.2.1]hept-5-ene
• Synonyms: 2-Azabicyclo[2.2.1]hept-5-ene;2-azabicyclo[2.2.1]hept-5-ene(SALTDATA: FREE);(1R,4S)-2-azabicyclo[2.2.1]hept-5-ene
• CAS NO: 6671-85-8
• Molecular Formula: C₆H₉N
• Molecular Weight: 95.15
• Mol File: 6671-85-8.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 137.6°C at 760 mmHg
• Flash Point: 33.3°C
• Appearance: /
• Density: 1.006g/cm³
• Vapor Pressure: 6.98mmHg at 25°C
• Refractive Index: 1.518
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.33±0.20(Predicted)
• CAS DataBase Reference: 2-Azabicyclo[2.2.1]hept-5-ene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Azabicyclo[2.2.1]hept-5-ene(6671-85-8)
• EPA Substance Registry System: 2-Azabicyclo[2.2.1]hept-5-ene(6671-85-8)

Safety Data

• Hazardous Substances Data: 6671-85-8(Hazardous Substances Data)

Usage

General Description

2-Azabicyclo[2.2.1]hept-5-ene, also known as norbornylene or 2-norbornene, is a bicyclic organic compound containing a seven-membered ring. It is a colorless liquid at room temperature and is mainly used as a monomer in polymerization reactions to produce polymers with high impact resistance and high heat resistance. It is also used as a starting material in the synthesis of various industrial chemicals and pharmaceuticals. Norbornylene is considered a valuable building block in organic chemistry due to its unique structure and reactivity, making it useful in a variety of applications in the chemical industry. Additionally, it is an important intermediate in the synthesis of bicycles and other organic compounds. Despite being relatively stable, it can undergo various chemical reactions, including polymerization, cycloaddition, and hydrogenation, further expanding its versatility in organic synthesis.

InChI:InChI=1/C6H9N/c1-2-6-3-5(1)4-7-6/h1-2,5-7H,3-4H2

Upstream product

• 49805-30-3 2-azabicyclo[2.2.1.]hept-5-en-3-one 
• 49805-30-3 racemic 2-azabicyclo[2.2.1]hept-5-en-3-one 
• 50-00-0 formaldehyd 
• 542-92-7 cyclopenta-1,3-diene 
• 2053-29-4 methyleneamine 
• 83953-54-2 2-azanorbornadiene 

Downstream Products

• 140927-07-7 2-(carbobenzyloxy)-2-azabicyclo<2.2.1>hept-5-ene 
• 81640-21-3 2-Benzoyloxy-2-azabicyclo<2.2.1>hept-5-en 
• 139927-14-3 (+/-)-2-benzoyl-2-azabicyclo<2.2.1>hept-5-ene 
• 81640-21-3 2exo-(Benzoyloxy)-2-azabicyclo<2.2.1>hept-5-en 
• 81640-21-3 2endo-(Benzoyloxy)-2-azabicyclo<2.2.1>hept-5-en 
• 188345-71-3 2-(tert-butoxycarbonyl)-2-azabicyclo[2.2.1]hept-5-ene 
• 286947-21-5 2-[(2-nitrophenyl)sulfonyl]-2-azabicyclo[2.2.1]hept-5-ene 
• 81640-28-0 N-Hydroxy-N-(2-methoxy-cyclopent-3-enylmethyl)-4-methyl-benzenesulfonamide 
• 81640-27-9 N-Hydroxy-N-(4-methoxy-cyclopent-2-enylmethyl)-4-methyl-benzenesulfonamide 
• 81640-25-7 3-(4-Methylphenylsulfonyl)-2-oxa-3-azabicyclo<3.2.1>oct-6-en 
• 81640-24-6 3-(4-Methylphenylsulfonyl)-2-oxa-3-azabicyclo<3.3.0>oct-7-en 
• 81640-26-8 3-Benzoyl-2-oxa-3-azabicyclo<3.3.0>oct-7-en 
• 81640-22-4 N-hydroxy-2-azabicyclo<2.2.1>hept-5-ene 
• 140927-17-9 2,2-Diphenyl-propionic acid (1R,4R,5R)-2-methyl-2-aza-bicyclo[2.2.1]hept-5-yl ester 

Relevant articles and documents

DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: I are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.

Design and synthesis of conformationally constrained N,N-disubstituted 1,4-diazepanes as potent orexin receptor antagonists

Orexins are neuropeptides that regulate wakefulness and arousal. Small molecule antagonists of orexin receptors may provide a novel therapy for the treatment of insomnia and other sleep disorders. In this Letter we describe the design and synthesis of con

BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. T